CH-0793076
Modify Date: 2025-08-28 22:32:16
CH-0793076 structure
|
Common Name | CH-0793076 | ||
|---|---|---|---|---|
| CAS Number | 534605-78-2 | Molecular Weight | 458.51 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C26H26N4O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CH-0793076CH-0793076 (TP3076), a hexacyclic camptothecin analog, is active drug and major metabolite of TP300. CH-0793076 inhibits DNA topoisomerase I with an IC50 of 2.3 μM. CH-0793076 is efficacious against cells expressing BCRP (breast cancer resistance protein)[1]. |
| Name | CH-0793076 |
|---|
| Description | CH-0793076 (TP3076), a hexacyclic camptothecin analog, is active drug and major metabolite of TP300. CH-0793076 inhibits DNA topoisomerase I with an IC50 of 2.3 μM. CH-0793076 is efficacious against cells expressing BCRP (breast cancer resistance protein)[1]. |
|---|---|
| Related Catalog | |
| Target |
Topoisomerase I:2.3 μM (IC50) |
| In Vitro | CH0793076 (TP3076) (6 days at 37°C) shows antiproliferative activity against PC-6/BCRP and PC-6/pRC cells, with IC50 of 0.35 and 0.18 nM[1]. |
| In Vivo | TP300 (1-100 mg/kg; bolus intravenous injection once per week for 3 weeks, for a total of three doses) shows more than 50% of tumor growth inhibition in all nine models, regardless of the expression of BCRP (WiDr, HT-29, NCI-H460 and AsPC-1, HCT116, COLO 201, HCT-15, Calu-6 and NCI-N87)[1]. |
| References |
| Molecular Formula | C26H26N4O4 |
|---|---|
| Molecular Weight | 458.51 |